What happens after complete withdrawal of therapy in patients with lupus nephritis

Clinical and Experimental Rheumatology

Volumn 31, Issue SUPPL.78, 2013, Pages

  Moroni, Gabriella ^a   Longhi, Selena ^a   Giglio, Elisa ^a   Messa, Piergiorgio ^a   Ponticelli, Claudio ^b  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^b HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

Author keywords

Corticosteroids therapy; Immunosuppressive therapy; Long term outcome; Lupus nephritis

Indexed keywords

AZATHIOPRINE; CHLORAMBUCIL; CHLOROQUINE; CORTICOSTEROID; CREATININE; CYCLOPHOSPHAMIDE; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE EXACERBATION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEINURIA; REMISSION; SYSTEMIC LUPUS ERYTHEMATOSUS; URINE SEDIMENT;

ADULT; CHI-SQUARE DISTRIBUTION; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS NEPHRITIS; MALE; PATIENT SELECTION; RECURRENCE; REMISSION INDUCTION; RISK FACTORS; STEROIDS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84885829041     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. BERTSIAS GK, TEKTONIDOU M, AMOURA Z et al.: Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis 2012; 71: 1771-82.
2. MORONI G, GALLELLI B, SINICO RA et al.: Rituximab versus oral cyclophosphamide for treatment of relapses of proliferative lupus nephritis: a clinical observationa study. Ann Rheum Dis 2012; 71: 1751-2.
3. HENDERSON LK, MASSON P, CRAIG JC et al.: Induction and maintenance treatment of proliferative lupus nephritis: a meta-analysis of randomized controlled trials. Am J Kidney Dis 2013; 61: 74-87.
4. LIU LL, JIANG Y, WANG LN et al.: Efficacy and safety of mycophenolate mofetil versus cyclophosphamide for induction therapy of lupus nephritis: a meta-analysis of randomized controlled trials. Drugs 2012; 72: 1521-33.
5. MAK A, CHEAK AA, TAN JY et al.: Mycophenolate mofetil is as efficacious as, but safer than, cyclophosphamide in the treatment of proliferative lupus nephritis: a metaanalysis and meta-regression. Rheumatology (Oxford) 2009; 48: 944-52.
6. MORONI G, DORIA A, MOSCA A et al.: A randomized pitol trial comparing cyclosporin and azathioprine for maintenance therapy of diffuse lupus nephritis over four years. Clin J Am Soc Nephrol 2006; 5: 925-32.
7. MERRILL JT, GINZLER EM, WALLACE DJ et al.: LBSL02/99 Study Group Long-term safety profile of belimumab plus standard therapy in patients with systemic lupus erythematosus. Arthritis Rheum 2012; 64: 3364-73.
8. PEPPER R, GRIFFITH M, KIRWAN C et al.: Rituximab is an effective treatment for lupus nephritis and allows a reduction in maintenance steroids. Nephrol Dial Transplant 2009; 24: 3717-23.
9. ROCCATELLO D, SCIASCIA S, ROSSI D et al.: Intensive short-term treatment with rituximab, cyclophosphamide and methylprednisolone pulses induces remission in severe cases of SLE with nephritis and avoids further immunosuppressive maintenance therapy. Nephrol Dial Transplant 2011; 26: 3987-9.
10. WALSH M, JAYNE D, MOIST L et al.: Practice pattern variation in oral glucocorticoid therapy after the induction of response in proliferative lupus nephritis. Lupus 2010; 19: 628-33.
11. MORONI G, GALLELLI B, QUAGLINI S et al.: Withdrawal of therapy in patients with proliferative lupus nephritis: long-term follow-up. Nephrol Dial Transplant 2006; 21: 1541-8.
12. HOCHBERG MC: Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725.
13. WEENING JJ, D'AGATI VD, SCHWARTZ MM et al.: The classification of glomerulonephritis in systemic lupus erythematosus revisited. Am Soc Nephrol 2004; 15: 241-50.
14. AUSTIN HA 3rd, BOUMPAS DT, VAUGHAN EM et al.: Predicting renal outcomes in severe lupus nephritis: contributions of clinical and histologic data. Kidney Int 1994; 45: 544-50.
15. MORONI G, QUAGLINI S, GALLELLI B et al.: The long-term outcome of 93 patients with proliferative lupus nephritis. Nephrol Dial Transplant 2007; 22: 2531-9.
16. PONTICELLI C, ALTIERI P, SCOLARI F et al.: A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy. J Am Soc Nephrol 1998; 9: 444-50.
17. Renal Disease Subcommittee of the American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Response Criteria: The American College of Rheumatology response criteria for proliferative and membranous renal disease in systemic lupus erythematosus clinical trials. Arthritis Rheum 2006; 54: 421-32.
18. MORONI G, QUAGLINI S, MACCARIO M et al.: "Nephritic flares" are predictors of bad long-term renal outcome in lupus nephritis. Kidney Int 1996; 50: 2047-53.
19. HOGAN J, APPEL GB: Update on the treatment of lupus nephritis. Curr Opin Nephrol Hypertens 2013; 22: 224-30.
20. MOSCA M, TANI C, CARLI L et al.: Glucocorticoids in systemic lupus erythematosus. Clin Exp Rheumatol 2011; 29: S126-9.
21. PONTICELLI C, GLASSOCK RJ, MORONI G: Induction and maintenance therapy in proliferative lupus nephritis. J Nephrol 2010; 23: 9-16.
22. NOSSENT J, CIKES N, KISS E et al.: Current causes of death in systemic lupus erythematosus in Europe, 2000--2004: relation to disease activity and damage accrual. Lupus 2007; 16: 309-17.
23. BERNATSKY S, BOIVIN JF, JOSEPH L et al.: Mortality in systemic lupus erythematosus. Arthritis Rheum 2006; 54: 2550-7.
24. APTEKAR RG, DECKER JL, STEINBERG AD: Exacerbation of SLE nephritis after cyclophosphamide withdrawal. N Engl J Med 1972; 286: 1159-60.
25. SHARON E, KAPLAN D, DIAMOND HS: Exacerbation of systemic lupus erythematosus after withdrawal of azathioprine therapy. N Engl J Med 1973; 288: 122-4.
26. PABLOS JL, GUTIERREZ-MILLET V, GOMEZREINO JJ: Remission of lupus nephritis with cyclophosphamide and late relapses following therapy withdrawal. Scand J Rheumatol 1994; 23: 142-4.
27. MOSCA M, NERI R, GIANNESSI S et al.: Therapy with pulse methylprednisolone and short course pulse cyclophosphamide for diffuse proliferative glomerulonephritis. Lupus 2001; 10: 253-5.
28. EULER HH, SCHROEDER JO, HARTEN P et al.: Treatment-free remission in severe systemic lupus erythematosus following synchronization of plasmapheresis with subsequent pulse cyclophosphamide. Arthritis Rheum 1994; 37: 1784-94.
29. GROOTSCHOLDEN C, BERDEN JOH: Discontinuation of immunosuppression in proliferative lupus nephritis: is it possible?. Nephrology Dialysis Transplantation 2006; 21: 1465-9.
30. MOK CC, YING KY, TANG S et al.: Predictors of outcome of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus glomerulonephritis. Arthritis Rheum 2004 Aug; 50: 2559-68.
31. LEE SJ, SILVERMAN E, BARGMAN JM: The role of antimalarial agents in the treatment od SLE and lupus nephritis. Nat Rev Nephrol 2011; 7: 718-29.
32. A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group. N Engl J Med 1991; 324: 150-4.
33. PONS-ESTEL GJ, ALARCóN GS, HACHUEL L et al.: Anti-malarials exert a protective effect while Mestizo patients are at increased risk of developing SLE renal disease: data from a Latin-American cohort. Rheumatology (Oxford) 2012; 5: 1293-8.